[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.12.79. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 149
Citations 0
Comment & Response
January 9, 2020

Concerns About Methodology in Study of Thyroid Nodule Gene Expression Classifier

Author Affiliations
  • 1Endocrinology, Veracyte, Inc, South San Francisco, California
JAMA Otolaryngol Head Neck Surg. Published online January 9, 2020. doi:10.1001/jamaoto.2019.4195

To the Editor Valderrabano et al1 question the sensitivity and specificity of the Afirma gene expression classifier (GEC) from its pivotal clinical validation, and by extension, its negative predictive value (NPV).2 I disagree with their methodology and conclusions.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×